LCG
ADPT icon

Lisanti Capital Growth’s Adaptive Biotechnologies ADPT Stock Holding History

Lisanti Capital Growth’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.97M Buy
+325,155
New +$4.98M 1.53% 14
2026
Q1 		– Sell
-142,515
Closed -$2.31M – 105
2025
Q4 		$2.31M Sell
142,515
-156,665
-52% -$2.56M 0.55% 76
2025
Q3 		$4.48M Buy
+299,180
New +$3.65M 1.09% 43

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Lisanti Capital Growth's ADPT Position: Q2 2026 in Review

Lisanti Capital Growth opened a new position in Adaptive Biotechnologies (ADPT) in Q2 2026: 325,155 shares worth $6.97M. The stake represents 1.53% of the portfolio and ranks #14 among its holdings. This is a return to the name: Lisanti Capital Growth previously reported a position in ADPT as recently as Q4 2025.

Lisanti Capital Growth first reported a position in ADPT in Q3 2025 and has held it in 3 quarters since. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Lisanti Capital Growth held 325,155 shares of Adaptive Biotechnologies worth $6.97M as of Q2 2026.
  • Adaptive Biotechnologies was a new Lisanti Capital Growth position in Q2 2026.
  • Adaptive Biotechnologies made up 1.53% of Lisanti Capital Growth's portfolio in Q2 2026, its #14 holding.
  • Lisanti Capital Growth first reported a position in Adaptive Biotechnologies in Q3 2025 and has held it in 3 quarters since.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Lisanti Capital Growth's 13F filing for Q2 2026, filed 10 Aug 2026.